The 12 kDa beta2-microglobulin (p2m) molecule is expressed in non-covalent association with the MHC Class I (HLA-ABC) glycoprotein heavy chain (Peterson et al., 1974) on the surface of most nucleated cells (Daar et al., 1984) . In addition to its release during cell membrane turnover, which occurs following internalisation of the HLA heavy chain (Cresswell et al., 1974) , 1n2m levels in the extracellular compartment may additionally result from direct cellular secretion (Nilsson et at., 1974; Conway & Poulik, 1976) . In broad terms, serum P2m concentrations have been shown to be of prognostic value in B-CLL and myelomatosis, apparently reflecting tumour cell mass (Norfolk et al., 1979; Simonsson et al., 1980; Spati et al., 1980; Child & Kushwaha, 1984 ; Bataille & Grenier, 1987) . This is particularly striking in myelomatosis where serum P2m can be used in the stratification and monitoring of disease. A progressive rise in serum P2m appears to accompany the onset of active disease in B-CLL (Simonsson et al., 1980) , and is paralleled by a greater in vitro P2m production rate by the leukaemic B-cells from active disease (Simonsson et al., 1986; Totterman et al., 1986) . The tumour itself is thus implicated as the source of increasing serum P2m, but since elevated levels are also observed in inflammatory and viral conditions (Plesner, 1980) , it is conceivable that these increased levels may in part be due to an immunological response to the malignancy.
Various immunoregulatory agents are known to influence lymphoid cell differentiation, often with corresponding stimulation of P2m production. Recent therapeutic advances have been noted in the treatment of conditions such as hairy cell leukaemia (HCL) by a-interferon (IFN-a) (Quesada et al., 1986; Genot et al., 1987) , a lymphokine which amongst others is known to increase the expression of cell-membrane 02m-associated determinants in vitro (Wallach et al., 1982) .
However, as relatively little is known about the in vitro response of leukaemic cells to these agents with respect to P2m production, we compared the inductive capacity of eight different immunoregulatory agents on the P2m production rates of both non-malignant tonsil and leukaemic B-cells.
Nisteri and Source and preparation of B-cellfractions
Non-malignant human B-cells Human non-malignant B-cells were obtained from four separate tonsils which were removed during routine tonsillectomy. After teasing of the tissue with scalpel and forceps, mononucler tonsil cells were isolated by Ficoll-Hypaque density gradient centrifugation (1.077 g ml-'; Lymphoprep, Nycomed, UK). Monocytes/macrophages were depleted by adherence to plastic Petri dishes (Nunc, Gibco) for 90min at 37C. The lymphocyte-rich non-adherent fraction was then T-cell depleted using a standard sheep erythrocyte rosetting technique whereby non-rosetting B-cells were obtained from the interface of a subsequent Ficoll gradient. The resulting tonsil lymphoid population comprised 0-1% monocytes (CD14 +), 1-2% T-cells (CD2 +, CD5 +), and exceeded 90% B-cells as defined by expression of CD19, CD20 and CD21.
Leukaemic B-cells Leukaemic cells from a total of 11 cases (clinical and haematological data detailed in Table I) were examined in this study. These were diagnostically classified as chronic lymphocytic leukaemia (B-CLL; n = 3), 'prolymphocytoid variants' of B-CLL (CLL-Pro; n = 5), non-Hodgkin's lymphoma (B-NHL; n = 1), prolymphocytic leukaemia (B-PLL; n = 1) and hairy cell leukaemia-proliferative variant (HCL-v; n = 1) on the basis of morphological appearances and immunophenotypic profiles as previously described (Melo et al., 1986; Drexler & Scott, 1989) . Mononuclear leukaemic cells were purified by density gradient centrifugation of heparinised blood on Ficoll-Hypaque and the harvested cells were examined immediately for the expression of lymphoid-associated membrane determinants by indirect immunofluorescence in suspension using a microtitre plate technique (Campana & Janossy, 1986) . Immunophenotyping reagents included polyclonal goat anti-human immunoglobulin heavy-and light-chain antibodies, and a wide range of murine anti-human monoclonal antibodies (Table II) . 11-55% PLC; B-PLL, >55% PLC (Melo et al., 1986) . dProliferative variant of hairy cell leukaemia; morphological and immunophenotypic features of HCI but in which functional studies were more in keeping with B-PLL (Scott et al., 1990) . 
Analysis of beta2-microglobulin (i2m) secretion
In vitro P2m production was determined by radioimmunoassay of cell-culture supernate samples, taken on successive days from cultures maintained at 2 x 106cells ml-' for up to 10 days. Mean rates of synthesis (ng ml-' (106 cells)-' day ') were calculated over the observed period of linear production, normally between days 2 and 6. Supernate P2m concentrations were measured using a modification of a previously described method (Swanson et al., 1982) . Briefly, monoclonal
anti-A,m antibody L368 (American Type Culture Collection), which was purified from hybridoma culture. medium by Protein-A chromatography, was incubated with 100,lO of 1:10 tonsil or leukaemic B-cell culture supernate and a standard amount of 125I-labelled soluble P2m. Following overnight incubation at 4°C and precipitation of immune complexes with 18% polyethylene glycol (PEG), the amount of precipitated activity was measured and the culture supernate P2m concentration thus calculated. Three internal P2m standard preparations, representing low (4.3 ng ml-' ), mid-range (37.5 ng ml-') and high (99.9 ng ml-') ligand concentrations, gave inter-assay variation coefficients (CV) of 16.3%, 6.7% and 6.5% respectively (n = 23). Intra-assay reproducibility, determined by replicate measurement of a single sample (mean 30.7 ngml-'; n = 10), was 4.5%.
Analysis of immunoglobulin production
Immunogobulin production by cultured B-cells was measured using a specific ELISA as described in detail previously (Drexler et al., 1988) .
Results
B2m production rates were determined in three cases of (Table V) Of the five different cytokines studied, IFN-y induced a greater increase in P2m production than did IFN-a, with relative production rates compared to control levels of 1.9 (range 1.5-3.2; n = 11) and 1.5 (range 1.3-1.8; n =6) respectively. Similarly, IL-2 induced P2m production to a greater degree than IL-1, with factors of 1.7 (range 1.0-2.3; n = 10) and 1.2 (range 0.9-1.7; n = 6) respectively. Culture in the presence of TNF alone did not significantly increase P2m production (1.1; range 0.9-1.2; n = 11) although TNF and IFN-y in combination produced a value of 1.8 (range 120 140 160 1.5-2.0; n = 7). There were no apparent differences in the response to these cytokines between non-malignant tonsil and leukaemic B-cell fractions. -interferon (rIFN-4) , y-interferon (rIFN-y), interleukins I and 2 (rIL-l, rIL-2) and tissue necrosis factor (rTNF)a 'Results are shown as absolute P2m production rates (ng ml-' (106 cells)' day-) in the presence or absence (control) of cytokines.
Production rate ratios, relative to the control (spontaneous) value, are shown in parentheses. bControl value indicates spontaneous P2m production obtained in the absence of cytokines. cCytokine concentrations as given in Materials and methods. dTwo cytokines used in combination.
of P2m production by tonsil and leukaemic B-cells. The spontaneous (control) P2m production rates for the tonsil B-cell fractions were broadly similar to those observed for the 'early' B-cell malignancies (B-CLL and CLL-Pro) whereas considerably higher unstimulated P2m production rates were found in all three 'late' B-cell proliferations (B-NHL, B-PLL and HCL-v). This appears contradictory as tonsil B-cells, despite their heterogeneity, show a more mature immunological membrane phenotype than B-CLL/CLL-Pro cells and, in terms of differentiation, are closer in ontogeny to malignant B-cell expansions such as B-NHL, B-PLL and HCL-v.
Of the activators and cytokines examined, TPA was the most potent stimulator of P2m production in both tonsil and leukaemic B-cells. Compared to the control cultures, TPA increased P2m production in the 11 non-malignant and leukaemic cases studied by a mean factor of 3.5. In addition, with the exception of one CLL-Pro case (PR) which showed a marked increase in TPA-induced P2m production and was the only B-cell malignancy examined with evidence of a proliferative component (12% nuclear Ki-67+), there were no significant differences in the levels of increased production between tonsil and leukaemic B-cells. However, different responses were apparent for tonsil and leukaemic B-cells when TPA was used in combination with the calcium mobilising ionophore A23187. An enhancement of TPA-induced P2m production occurred in tonsil B-cells, whereas A23 187 appeared to exert a suppressive effect on TPA-induced production in most of the B-cell malignancies. When used singly, A23187 failed to enhance P2m production much above control levels in three of four cases of B-cell malignancy, but induced a modest increase in production rate for all four tonsil B-cell cultures. Although we are not aware of the significance of these different responses between 'normal' and leukaemic B-cells, a potential consideration is that the former become activated and proliferate in the presence of TPA whereas the latter are induced to differentiate with little or no proliferation (Bartoglio, 1983; Drexler et al., 1988) . However, the one case included in this study with evidence of 'low level' proliferation (case PR) showed response patterns to the stimulus of A23 187 and TPA/A23 187 which were more similar to the other (non-proliferating) leukaemic B-cell cases than to tonsil B-cells. The ratio of TPA-induced P2m production to spontaneous P2m production was particularly striking in this case, but whether this finding is a reflection of the proliferation process is not known.
A previous study of leukaemic B-cells in 22 cases of B-CLL (Simonsson et al., 1986) showed that the mean spontaneous in vitro P2m production rate in 12 patients with progressive disease (NCI committee criteria for CLL) was No apparent differences in the response of tonsil and leukaemic B-cells to the immunoregulatory agents IL-1, IL-2, IFN-y, IFN-a and TNF were seen. The stimulatory capacity of IL-2 was found to be greater than IL-1, and IFN-y was greater than IFN-a but in almost no case was the stimulation of P2m production as extensive as that produced by TPA or bryostatin-1. Although TNF and IFN-'y have been reported to act synergistically in enhancing MHC class I (and therefore P2m) expression (Pfizenmaier et al., 1987) , this was clearly not the case in terms of P2m export, as the production rate by IFN-y/TNF-stimulated cells was not apparently greater than that of cells stimulated by IFN-y alone.
The precise significance of enhanced P2m production with stimulation has not been established, but it may simply reflect the degree of differentiation thus induced. It is generally accepted that the stage of B-cell differentiation is broadly reflected by the IgM secretion rate. However, it is apparent from this study that, despite the slight (P <0.05) correlation between the spontaneous P2m and IgM secretion rates, that the degree of leukaemic cell differentiation appears more closely correlated with the P2m production rate.
Moreover, the suppression in TPA-induced P2m production rates observed when TPA and A23187 were used in combination was not apparent for IgM secretion rates. The measurement of P2m production rates could therefore be of potentially more value than IgM production rates in assessing the response of leukaemic cells to biomodulating agents. Hence, using P2m production rate as an index of response, the recominant cytokines IL-1, IL-2, IFN-y, IFN-a and TNF were considerably less potent than TPA (with or without calcium ionophore), which is at least consistent with previous observations (Drexler et al., 1988; Drexler, unpublished observations) showing that such stimuli are not at all, or only weakly, efficient in inducing B-CLL differentiation.
Alternatively, the level of spontaneous P2m production might represent a marker for the degree of activation of a B-cell. It is noteworthy that in 8/11 of the leukaemic populations examined, the control P2m production rates were higher than those of the tonsil B-cell fractions. Based on their cytomorphological and surface antigen (SIg) features, B-CLL cells were originally considered as the malignant counterparts of small resting B-cells (Robert et al., 1986 ). However, recent functional studies suggested that B-CLL cells are arrested in an 'activated' state (Beiske et al., 1988) that is reflected by the expression of one or more activation-associated antigens such as FMC7, UCHB1, CD25, B5 or B7 (Table III) . Furthermore, the morphology of B-PLL cells and B-CLL cells in 'prolymphocytoid transformation' (CLL-Pro) resembles that described for activated normal B-cells (Melo et al., 1986) .
Thus, viewed in these terms, our data on spontaneous P2m secretion supports the contention that the leukaemic cells from B-CLL, CLL-Pro and, in particular, B-PLL represent cells at an activated stage of B-cell differentiation.
We also analysed the effects of the new protein kinase C stimulator bryostatin-1. In contrast to phorbol esters, bryostatin-1 lacks tumour-promoting activity and even has anti-neoplastic properties (Blumberg, 1988) . The naturally occurring bryostatin-1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, binds to protein kinase C and, like TPA, stimulates its activity. However, bryostatin-1 induces only some of the responses obtained with phorbol esters and may even block TPA-mediated responses in some experimental situations . The 'weaker' effects of bryostatin-l on some parameters might be explained by a more transient action for bryostatins associated with accelerated breakdown of protein kinase C.
In our study, bryostatin-1 was effective in inducing P2m production, particularly in combination with A23187, but the levels of P2m induced by bryostatin-l used singly were significantly lower than those found in cultures exposed to TPA. In tonsil B-cells, the combination of bryostatin-1 and A23187 was not as stimulatory for P2m production as was the TPA/A23187 combination, whereas for leukaemic B-cells, the two combinations had approximately equal potency. This was probably an indirect result, in these particular cases, of the suppressive effect on TPA-induced P2m production by A23187.
Finally, this study supports previous evidence that the signal transduction pathway distal to protein kinase C is intact in B-CLL and related leukaemic cells and can be stimulated effectively by protein kinase C agonists such as TPA or bryostatin-l (Drexler et al., 1988 .
